PT  - JOURNAL ARTICLE
AU  - Bolze, Alexandre
AU  - Cirulli, Elizabeth T.
AU  - Luo, Shishi
AU  - White, Simon
AU  - Cassens, Tyler
AU  - Jacobs, Sharoni
AU  - Nguyen, Jason
AU  - Ramirez, Jimmy M.
AU  - Sandoval, Efren
AU  - Wang, Xueqing
AU  - Wong, David
AU  - Becker, David
AU  - Laurent, Marc
AU  - Lu, James T.
AU  - Isaksson, Magnus
AU  - Washington, Nicole L.
AU  - Lee, William
TI  - Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States
AID  - 10.1101/2021.06.20.21259195
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.20.21259195
4099  - http://medrxiv.org/content/early/2021/06/21/2021.06.20.21259195.short
4100  - http://medrxiv.org/content/early/2021/06/21/2021.06.20.21259195.full
AB  - The SARS-CoV-2 variant of concern B.1.617.2 displaced B.1.1.7 as the dominant variant in England and other countries. This study aimed to determine whether B.1.617.2 was also displacing B.1.1.7 in the United States. We analyzed PCR testing results and viral sequencing results of samples collected across the United States, and showed that B.1.1.7 was rapidly being displaced and is no longer responsible for the majority of new cases. The percentage of SARS-CoV-2 positive cases that are B.1.1.7 dropped from 70% in April 2021 to 42% in just 6 weeks. Our analysis showed rapid growth of variants B.1.617.2 and P.1 as the primary drivers for this displacement. Currently, the growth rate of B.1.617.2 was higher than P.1 in the US (0.61 vs. 0.22), which is consistent with reports from other countries. Lastly, we showed that B.1.617.2 was growing faster in counties with a lower vaccination rate.Competing Interest StatementA.B., E.T.C., S.L., S.W., T.C., S.J., J.N., J.M.R., E.S., X.W., D.W., D.B., M.L., J.T.L., M.I., N.L.W. and W.L. are employees of Helix.Funding StatementThis work has been funded in part by CDC BAA contracts 75D30121P10258 (Illumina, Helix). This work was also funded in part by Helix internal funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Helix data analyzed and presented here were obtained through IRB protocol WIRB#20203438, which grants a waiver of consent for a limited dataset for the purposes of public health under section 164.512(b) of the Privacy Rule (45 CFR 164.512(b)).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this manuscript can be accessed on Helix Github COVID page: https://github.com/myhelix/helix-covid19db. Sequences are also available on GISAID. https://github.com/myhelix/helix-covid19db